The antagonist cannabinol and the agonist WS12 for TRPM8 can rapidly desensitize and inhibit the growth of colorectal cancer xenografts and the occurrence of chemically induced colon cancer, highlighting the potential of TRPM8 as a CRC drug target [49, 50]. Here, TRPM8 is linked to colorectal carcinoma.